rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Capricor Therapeutics, Inc.

CAPR · Nasdaq

Health CareBiotechnologyNot moving yet

CAPR stood above a rising 150-day average in 28 of the last 52 weekly readings, and has been out of that trend for the last 17 weeks. It is 66.9% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 17
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$16.7M
Officials’ trades on record
2
Institutions holding
164 (-5)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 28 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$6.5M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

2 disclosed lines: House 2, Senate 0, executive 0; 1 people.

WhoDidAmountTraded
Roger Marshall House: U.S. House ClerkKS01bought$1k–$15k27 Jul 2017filed 6 Aug 2018
Roger Marshall House: U.S. House ClerkKS01solddependent child$1k–$15k27 Jul 2017filed 6 Aug 2018

Insiders

Buy orders, 12 months0
Sale orders, 12 months13
Buyers · sellers0 · 3
WhoDidSharesTraded
Karen KrasneyEVP, GENERAL COUNSELsold24,100at $30.3825 Jun 2026filed 29 Jun 2026
Anthony BergmannCHIEF FINANCIAL OFFICERsold24,100at $30.3825 Jun 2026filed 29 Jun 2026
Karen KrasneyEVP, GENERAL COUNSELsold400at $30.0024 Jun 2026filed 24 Jun 2026
Anthony BergmannCHIEF FINANCIAL OFFICERsold400at $30.0024 Jun 2026filed 24 Jun 2026
Karen KrasneyEVP, GENERAL COUNSELsold500at $30.0022 Jun 2026filed 24 Jun 2026
Anthony BergmannCHIEF FINANCIAL OFFICERsold500at $30.0022 Jun 2026filed 24 Jun 2026
Karen KrasneyEVP, GENERAL COUNSELsold25,000at $31.701 May 2026filed 4 May 2026
Anthony BergmannCHIEF FINANCIAL OFFICERsold25,000at $31.701 May 2026filed 4 May 2026
Karimah Es SabarDirectorsold7,529at $32.002 Apr 2026filed 3 Apr 2026
Karimah Es SabarDirectorsold53,735at $31.031 Apr 2026filed 1 Apr 2026
Karen KrasneyEVP, GENERAL COUNSELsold25,000at $30.1231 Mar 2026filed 1 Apr 2026
Anthony BergmannCHIEF FINANCIAL OFFICERsold25,000at $30.1331 Mar 2026filed 1 Apr 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders164-5 on the quarter
New · exited31 · 35
Reported value$932.9M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20264,145,061$99.8M+723,246+21.1%
TANG CAPITAL MANAGEMENT LLCadded · filed 14 Aug 20264,099,900$98.7M+700,000+20.6%
MONTANOVA CAPITAL, LLCadded · filed 14 Aug 20264,092,784$98.6M+274,184+7.2%
STATE STREET CORPadded · filed 7 Aug 20263,397,150$81.8M+1,215,249+55.7%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20262,297,674$55.3M+269,942+13.3%
GOLDMAN SACHS GROUP INCadded · filed 14 Aug 20261,578,131$38.0M+666,155+73.0%
RA CAPITAL MANAGEMENT, L.P.unchanged · filed 14 Aug 20261,507,844$36.3M00.0%
Boxer Capital Management, LLCadded · filed 14 Aug 20261,395,156$33.6M+805,156+136.5%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20261,372,286$33.0M+253,960+22.7%
FMR LLCadded · filed 13 Aug 20261,137,730$27.4M+365,081+47.3%
31 Mar 2023 – 30 Jun 2026
2896164Mar 23Dec 23Dec 24Sep 25Jun 26

News

Everyone who traded it

Anthony Bergmann Company insiderCHIEF FINANCIAL OFFICER · last 25 Jun 20261 · 5
Karen Krasney Company insiderEVP, GENERAL COUNSEL · last 25 Jun 20262 · 5
Michael T. Maurer Company insiderCHIEF COMMERCIAL OFFICER · last 26 May 20260 · 0
Frank Litvack Company insiderDirector · last 13 May 20260 · 0
Karimah Es Sabar Company insiderDirector · last 2 Apr 20260 · 3
David B. Musket Company insiderDirector · last 5 Jan 20265 · 2
George W. Dunbar Jr. Company insiderDirector · last 5 Jan 20260 · 0
Linda Marban Company insiderCHIEF EXECUTIVE OFFICER · last 5 Jan 20264 · 0
Mike Kelliher Company insiderDirector · last 5 Jan 20260 · 0
Paul Gisbert Auwaerter Company insiderDirector · last 5 Jan 20261 · 0
Philip J. Gotwals Company insiderDirector · last 5 Jan 20260 · 0
Earl M. Collier, Jr. Company insiderDirector · last 27 Feb 20251 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-33.8%
Share count trendFY 2025 · to 16 Mar 20260.2%
Cash and equivalentsFY 2025 · to 31 Dec 2025$287.8M
Free cash flowFY 2025 · to 31 Dec 2025−$72.7M

Analyst forecasts

No analyst forecasts yet.